<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017108</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068650</org_study_id>
    <secondary_id>EORTC-06992-CLL-3</secondary_id>
    <nct_id>NCT00017108</nct_id>
  </id_info>
  <brief_title>Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. It is not yet known which chlorambucil regimen is more effective&#xD;
      in treating advanced chronic lymphocytic leukemia.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of different regimens of&#xD;
      chlorambucil in treating patients who have advanced chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare overall and disease-related survival of patients with B-cell chronic lymphocytic&#xD;
           leukemia treated with high-dose chlorambucil induction therapy with or without low-dose&#xD;
           chlorambucil maintenance therapy.&#xD;
&#xD;
        -  Compare the time to salvage treatment in these patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Compare the treatment-related mortality of these patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center, time to complete response (before 12 weeks vs after 12 weeks vs partial&#xD;
      response), and cytopenia at diagnosis (Binet stage A+B vs C).&#xD;
&#xD;
      All patients receive induction therapy comprising high-dose oral chlorambucil daily.&#xD;
      Treatment continues until achievement of complete response or a maximum of 24 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who respond to induction therapy are randomized to 1 of 2 treatment arms for&#xD;
      maintenance therapy.&#xD;
&#xD;
        -  Arm I: Patients receive low-dose oral chlorambucil twice a week. Therapy continues for&#xD;
           up to 5 years in the absence of disease progression or unacceptable toxicity. If disease&#xD;
           progression occurs, then patients may proceed to salvage therapy.&#xD;
&#xD;
        -  Arm II: Patients receive no maintenance therapy. If disease progresses, patients receive&#xD;
           induction therapy again. If disease does not respond to re-induction therapy, then&#xD;
           patients may proceed to salvage therapy.&#xD;
&#xD;
        -  Salvage therapy: Patients with progressive disease during maintenance therapy receive&#xD;
           fludarabine IV daily and cyclophosphamide IV daily on days 1-3. Treatment repeats every&#xD;
           4 weeks for 3-6 courses.&#xD;
&#xD;
      Patients are followed monthly for 3 months, every 2 months for 6 months, and then every 3&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 470 patients will be accrued for this study within 4.7&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorambucil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of B-cell chronic lymphocytic leukemia&#xD;
&#xD;
               -  Co-expression of CD5/CD19 or CD5/CD20 positivity, dim sIg, and CD23 positivity&#xD;
&#xD;
               -  Previously untreated advanced disease defined as presence of at least 1 of the&#xD;
                  following:&#xD;
&#xD;
                    -  Total tumor mass (TTM) score greater than 9&#xD;
&#xD;
                    -  TTM doubling time less than 12 months&#xD;
&#xD;
                    -  Bone marrow failure (platelet count less than 100,000/mm^3 and/or hemoglobin&#xD;
                       less than 10 g/dL)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Hepatitis B negative&#xD;
&#xD;
          -  No active hepatitis C&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 3 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance greater than 0.5 times normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No severe cardiovascular disease&#xD;
&#xD;
          -  No arrhythmia requiring chronic treatment&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No symptomatic ischemic heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled systemic infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior or concurrent uncontrolled malignancy&#xD;
&#xD;
          -  No prior or concurrent central nervous system or psychiatric disorders requiring&#xD;
             hospitalization&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior steroid therapy for less than 2 weeks allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Branimir Jaksic, MD, PhD</last_name>
    <affiliation>University of Zagreb Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital</name>
      <address>
        <city>Kaposvar</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Skopje</name>
      <address>
        <city>Skopje</city>
        <zip>91000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leyenburg Ziekenhuis</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Escolar San Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </location_countries>
  <verification_date>June 2004</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

